Macuject develops clinical decision support software for macular disease, specifically focusing on age-related macular degeneration (AMD). The software assists doctors in improving treatment decisions and patient management.

Macuject

Macuject | 1,257 followers on LinkedIn. Combining AI insights with human expertise to end preventable blindness
 | Macuject is a clinician-driven digital health company created to end preventable blindness for tens of millions across the globe, starting with age-related macular degeneration (AMD); diabetic retinopathy, cataract and glaucoma will follow.
 
Our innovative clinical decision support software is specifically designed to address both wet and dry forms of AMD, empowering healthcare professionals to make accurate and timely diagnoses, optimise treatment plans, and monitor disease progression more effectively. By harnessing the power of cutting-edge artificial intelligence and integrating seamlessly with existing medical infrastructure, our SaaS solutions enable early intervention and personalized care, dramatically improving patient outcomes and significantly reducing the social and economic burden of these blinding conditions.

Chief Operating Officer

Peter Girling

Eric Bernabei

CEO-founder @ Macuject | MD

Devinder Chauhan

Machine Learning and AI Lead @ Macuject | PhD, ML Ops, Deep Learning, Computer Vision

Gihan Samarasinghe

If you're going to the #AAO24 in Chicago, register for the first Annual AI in GA summit, where Macuject CEO-founder Devinder Chauhan will be speaking along with several of the experts and companies in this space

Thank you Giacomo Boscia for your great presentation of quantitative fluid dynamics following switch to faricimab, using Macuject 's automated #AI , in collaboration with SriniVas Sadda 's team at Doheny Eye Institute . #ARVO2024 #agerelatedmaculardegeneration #preventblindness #faricimab #antivegf #fluiddynamics #artificialintelligence

And thats a wrap on Association for Research in Vision and Ophthalmology (ARVO) 2024! Thank you for another great year in research, especially to our collaborators at the Doheny Eye Institute . See you next year!

One more day of Association for Research in Vision and Ophthalmology (ARVO) presentations to come. We'll see you in 612 Arch Building at 2.45pm Thursday!

Two more poster presentations are just around the corner! If you're at this years Association for Research in Vision and Ophthalmology (ARVO) be sure to come over to poster board A0130 this Wednesday from 10.30am to discuss with our associates at Doheny Eye Institute various #realworldevidence outcomes of faricimab patients. See you there!

Next up, a paper presentation by Ayesha Karamat in conjunction with the Doheny Eye Institute this Tuesday 7th May at Association for Research in Vision and Ophthalmology (ARVO) 2024. See you there!

Association for Research in Vision and Ophthalmology (ARVO) is finally here for 2024! Swetha Velaga is first up for Macuject 's 6 total projects in conjunction with Doheny Eye Institute at poster board A0130 at 3pm this Monday. Followed by Giacomo Boscia talking #realworldevidence in the treatment of #maculardegernation using #faricimab . Be sure not to miss his presentation at 4.30pm. See you soon!

This years Association for Research in Vision and Ophthalmology (ARVO) is almost here! We are beyond pleased to have 3 paper sessions and 3 posters of #realworldevidence focussed on #maculardegeneration being presented in collaboration with Doheny Eye Center UCLA - Pasadena Mark it down in your calendars! #agerelatedmaculardegeneration #machinelearning #realworldevidence

Not only the marrying of #rubyonrails and the world of #maculardegeneration but also a number of our CTO Bradley Beddoes favourite dad jokes! Incredibly grateful for the hard work of he and developer Bianca Power for their now available talk at #RubyConfAU this year. Have a listen!

This years Digital Health Festival , our very own COO Peter Girling !

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 6, 2024 3:16 PM	e0f7f6d6
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 6, 2024 3:16 PM	65fa6e23
crunchbase trigger	general	Nov 6, 2024 3:16 PM	1506897e
crunchbase profile	general
li profile	general	Nov 6, 2024 3:16 PM	e7a18ca1
translate crunchbase fundingrounds	general
peers	general	Nov 6, 2024 3:16 PM	de2e3478
news basic	general	Nov 6, 2024 3:16 PM	b21dde50
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

MACU

COM:MACUJECT

Macuject